Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip Bruggmann

Showing results (11-20 of 86) with videos related to

Pageof 9
Sort By:
Health Research Policy and Systems|February 15, 2022
How to set the agenda for hepatitis C: a theory-driven policy analysisJulia Kind, Bettina Maeschli, Philip Bruggmann
The European Journal of General Practice|April 27, 2011
Chronic Hepatitis C virus infection in Swiss primary care practices: low case loads-high barriers to treatment?Kathrin Overbeck, Philip Bruggmann, Beat Helbling
Praxis|April 15, 2016
[Problematic alcohol use]Tibor Rasovszky, Philip Bruggmann, Thilo Beck
The International Journal on Drug Policy|September 13, 2021
Hepatitis C reinfection following successful direct-acting antiviral therapy among patients attending a multidisciplinary treatment centre for people who use drugs in Zurich, SwitzerlandLuis Falcato, Claudia Bernardini, Philip Bruggmann
Swiss Medical Weekly|May 28, 2023
Evidence of use and users of image- and performance-enhancing drugs in sports in Switzerland: a scoping literature review and implications for Swiss drug policyMuriel Kruijver, Philip Bruggmann, Raphael Magnolini
BMC Public Health|May 29, 2008
An integrated model of care to counter high incidence of HIV and sexually transmitted diseases in men who have sex with men - initial analysis of service utilizers in ZurichDavid L B Schwappach, Philip Bruggmann
The International Journal on Drug Policy|October 28, 2018
Direct-acting antiviral therapy for hepatitis C infection among people receiving opioid agonist treatment or heroin assisted treatmentNathalie Scherz, Philip Bruggmann, Nathalie Brunner
European Journal of Gastroenterology & Hepatology|January 22, 2024
Late presentation for hepatitis C treatment: prevalence and risk factors in the Swiss Hepatitis C CohortNathalie Brunner, Thomas Grischott, Philip Bruggmann, et al.
Praxis|September 18, 2014
[Treatment of hepatitis C - an imminent revolution]Verena Schärer, Philip Bruggmann, Beat Müllhaupt, et al.
Swiss Medical Weekly|February 7, 2015
Hepatitis C: a changing epidemicGilles Wandeler, Jean-François Dufour, Philip Bruggmann, et al.
Pageof 9

Showing results (11-20 of 86) with videos related to

Sort By:
Pageof 9
Health Research Policy and Systems|February 15, 2022
How to set the agenda for hepatitis C: a theory-driven policy analysisJulia Kind, Bettina Maeschli, Philip Bruggmann
The European Journal of General Practice|April 27, 2011
Chronic Hepatitis C virus infection in Swiss primary care practices: low case loads-high barriers to treatment?Kathrin Overbeck, Philip Bruggmann, Beat Helbling
Praxis|April 15, 2016
[Problematic alcohol use]Tibor Rasovszky, Philip Bruggmann, Thilo Beck
The International Journal on Drug Policy|September 13, 2021
Hepatitis C reinfection following successful direct-acting antiviral therapy among patients attending a multidisciplinary treatment centre for people who use drugs in Zurich, SwitzerlandLuis Falcato, Claudia Bernardini, Philip Bruggmann
Swiss Medical Weekly|May 28, 2023
Evidence of use and users of image- and performance-enhancing drugs in sports in Switzerland: a scoping literature review and implications for Swiss drug policyMuriel Kruijver, Philip Bruggmann, Raphael Magnolini
BMC Public Health|May 29, 2008
An integrated model of care to counter high incidence of HIV and sexually transmitted diseases in men who have sex with men - initial analysis of service utilizers in ZurichDavid L B Schwappach, Philip Bruggmann
The International Journal on Drug Policy|October 28, 2018
Direct-acting antiviral therapy for hepatitis C infection among people receiving opioid agonist treatment or heroin assisted treatmentNathalie Scherz, Philip Bruggmann, Nathalie Brunner
European Journal of Gastroenterology & Hepatology|January 22, 2024
Late presentation for hepatitis C treatment: prevalence and risk factors in the Swiss Hepatitis C CohortNathalie Brunner, Thomas Grischott, Philip Bruggmann, et al.
Praxis|September 18, 2014
[Treatment of hepatitis C - an imminent revolution]Verena Schärer, Philip Bruggmann, Beat Müllhaupt, et al.
Swiss Medical Weekly|February 7, 2015
Hepatitis C: a changing epidemicGilles Wandeler, Jean-François Dufour, Philip Bruggmann, et al.
Pageof 9